Primary Sclerosing Cholangitis - Symptoms, Causes, Treatment & Prevention

```html

Overview

Primary sclerosing cholangitis (PSC) is a chronic, progressive disease that causes inflammation and scarring (fibrosis) of the bile ducts inside and outside the liver. The scarring narrows the ducts, obstructing the flow of bile—a digestive fluid that helps the liver break down fats and eliminate toxins. Over time, this can lead to liver damage, cirrhosis, and liver failure.

PSC most commonly affects adults between the ages of 30 and 50, but it can appear at any age, including in children. It is far more prevalent in men than women (approximately 2–3 : 1). The exact prevalence is unclear because the disease is rare; estimates range from 1 to 16 cases per 100,000 people worldwide, with the highest rates reported in Northern Europe and North America.

The condition is strongly associated with inflammatory bowel disease (IBD), especially ulcerative colitis. More than 70 % of people with PSC also have IBD, and conversely, about 5 % of patients with ulcerative colitis develop PSC.

Symptoms

Symptoms often develop slowly and can be vague early on. Many patients are diagnosed incidentally during imaging for unrelated reasons. When symptoms do appear, they may include:

• Fatigue – persistent tiredness not relieved by rest.
• Pruritus (itchy skin) – caused by bile salts depositing in the skin; often worsens at night.
• Jaundice – yellowing of the skin and whites of the eyes due to elevated bilirubin.
• Abdominal pain – typically a dull, right‑upper‑quadrant discomfort.
• Dark urine and pale stools – result of reduced bile reaching the intestines.
• Weight loss – secondary to malabsorption of fats and fat‑soluble vitamins.
• Fever & chills – may signal an infection such as cholangitis.
• Night sweats – sometimes present in advanced disease or with associated cancer.
• Joint pain – especially in patients who also have IBD (a type of peripheral arthritis).

Because many of these signs overlap with other liver or gastrointestinal disorders, proper evaluation is essential.

Causes and Risk Factors

The precise cause of PSC remains unknown, but several mechanisms are believed to contribute:

• Autoimmune dysregulation – the immune system mistakenly attacks bile‑duct cells.
• Genetic susceptibility – certain HLA haplotypes (e.g., HLA‑B8, HLA‑DR3) increase risk.
• Gut‑liver axis disturbances – alterations in intestinal microbiota may trigger inflammation of the bile ducts.
• Environmental triggers – smoking, infections, or exposure to certain chemicals have been investigated, but data are inconclusive.

Who is at higher risk?

• Men aged 30‑50.
• Individuals with ulcerative colitis or, less commonly, Crohn’s disease.
• People who carry HLA‑B8, DR3, or DR4 alleles.
• Family history of PSC or other autoimmune liver diseases.
• Patients with a history of recurrent bacterial cholangitis.

Diagnosis

Diagnosing PSC involves a combination of clinical evaluation, blood tests, imaging, and sometimes tissue sampling.

Laboratory tests

• Liver function tests (LFTs) – typically show an elevated alkaline phosphatase (ALP) and gamma‑glutamyl transpeptidase (GGT); transaminases (AST/ALT) may be mildly raised.
• Serum bilirubin – becomes elevated in advanced disease.
• Autoantibodies – p‑ANCA is positive in 60‑80 % of cases; ANA and anti‑SMA can also be present.
• Vitamin levels – especially fat‑soluble vitamins (A, D, E, K) which may be low.

Imaging studies

• Magnetic resonance cholangiopancreatography (MRCP) – the preferred, non‑invasive test; shows characteristic multifocal strictures and beading of intra‑ and extra‑hepatic bile ducts.
• Endoscopic retrograde cholangiopancreatography (ERCP) – provides detailed images and allows therapeutic interventions (e.g., stenting) but carries a higher risk of complications, so it is usually reserved for cases requiring intervention.
• Ultrasound – useful for screening for gallstones and assessing liver size but less specific for PSC.
• Liver biopsy – not required for diagnosis but may be performed to assess disease stage or rule out overlap syndromes (e.g., autoimmune hepatitis).

Diagnostic criteria (simplified)

1. Persistent cholestatic LFT pattern (elevated ALP/GGT) > 6 months.
2. Imaging evidence of multifocal biliary strictures on MRCP or ERCP.
3. Exclusion of secondary causes (e.g., biliary stones, infections, drug‑induced cholangitis).

Treatment Options

There is currently no cure for PSC, and treatment focuses on slowing disease progression, managing symptoms, and preventing complications.

Medication

• Ursodeoxycholic acid (UDCA) – a bile‑acid that may improve liver enzymes but has not consistently shown survival benefit; low‑dose regimens (13‑15 mg/kg) are sometimes used under specialist guidance.
• Obeticholic acid – an FXR agonist under investigation; may improve cholestasis in early trials.
• Antibiotics – oral or biliary‑directed antibiotics (e.g., fluoroquinolones, rifaximin) are used to treat bacterial cholangitis.
• Immunosuppressants – limited efficacy; some clinicians trial steroids or azathioprine in overlap syndromes.
• Pruritus relief – cholestyramine (binding bile acids), rifampin, naltrexone, or sertraline.
• Fat‑soluble vitamin supplementation – vitamins A, D, E, K.

Procedural interventions

• Endoscopic dilation or stenting – to relieve dominant strictures that cause jaundice or cholangitis.
• Balloon‐assisted cholangioscopy – newer technique for targeted therapy.
• Liver transplantation – the only definitive treatment for end‑stage disease; 5‑year post‑transplant survival exceeds 80 % (UNOS data).

Lifestyle & supportive measures

• Quit smoking – smoking worsens IBD and may accelerate liver disease.
• Maintain a balanced diet rich in omega‑3 fatty acids, fruits, and vegetables; limit saturated fats and simple sugars.
• Regular moderate exercise – improves fatigue and overall cardiovascular health.
• Avoid alcohol or limit intake to < 20 g/day (women) / < 30 g/day (men) and discuss any consumption with your hepatologist.
• Vaccinations – hepatitis A & B, pneumococcal, influenza, and COVID‑19 boosters.

Living with Primary Sclerosing Cholangitis

Adapting to PSC is a lifelong process. Below are practical tips for day‑to‑day management:

Monitoring

• Schedule liver function panel every 3–6 months (more frequently if labs are unstable).
• Annual imaging (MRCP) to track bile‑duct changes.
• Colonoscopic surveillance every 1–2 years for patients with IBD, as PSC dramatically increases the risk of colorectal cancer.

Symptom control

• Pruritus – apply cool compresses, use moisturizers, and take cholestyramine before bedtime.
• Fatigue – prioritize sleep hygiene, incorporate short “power naps,” and discuss low‑dose stimulants with your physician if needed.
• Digestive issues – consider a pancreatic enzyme supplement if stools are greasy; a dietitian can tailor a low‑fat, high‑calorie plan.

Emotional health

• Join support groups (e.g., PSC Support, local liver disease foundations) to share experiences.
• Consider counseling or cognitive‑behavioral therapy to cope with chronic illness anxiety.
• Stay informed but avoid excessive internet searching; trust information from reputable sources (Mayo Clinic, NIH, etc.).

Work and daily activities

• Communicate with your employer about potential fatigue or medical appointments.
• Plan for flexibility in travel; carry a medication list and know the location of nearby hospitals.
• Stay hydrated and move regularly to prevent blood‑clotting issues associated with liver disease.

Prevention

Because the exact cause of PSC is unknown, primary prevention is limited. However, measures that reduce overall liver stress and support immune health may lower risk:

• Control inflammatory bowel disease – early and consistent treatment of ulcerative colitis appears to lessen PSC onset.
• Avoid hepatotoxic substances – limit exposure to industrial chemicals, certain herbal supplements, and high‑dose acetaminophen.
• Vaccinations – protect the liver from viral hepatitis, a known co‑factor for worsening liver disease.
• Healthy lifestyle – balanced diet, regular exercise, and smoking cessation reduce systemic inflammation.

Complications

If left untreated or if disease progresses, PSC can lead to serious health problems:

• Cirrhosis – scarring of the liver that impairs its function; may lead to portal hypertension.
• Portal hypertension – variceal bleeding, ascites, splenomegaly.
• Cholangiocarcinoma (bile‑duct cancer) – incidence 10–15 % over 20 years; screening with CA 19‑9 and imaging is recommended.
• Colorectal cancer – risk is 4–5 times higher in PSC‑IBD patients; intensive colonoscopic surveillance is essential.
• Gallbladder disease – stones, polyps, or cancer; an annual gallbladder ultrasound is advised.
• Bone disease – osteoporosis due to malabsorption of vitamin D and chronic cholestasis.
• Liver failure – may require transplantation.

When to Seek Emergency Care

---

Key References

• Mayo Clinic. “Primary sclerosing cholangitis.” Link.
• Cleveland Clinic. “Primary Sclerosing Cholangitis Overview.” Link.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “PSC.” Link.
• European Association for the Study of the Liver (EASL) Clinical Practice Guidelines, 2016.
• American Association for the Study of Liver Diseases (AASLD) Guidance on Cholangiocarcinoma Screening, 2021.
• World Health Organization. “Global Health Estimates 2022.”

```